Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 2019-2020, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Turner, M. L.
Right arrow Articles by Acosta, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Turner, M. L.
Right arrow Articles by Acosta, E. P.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2000;46:2019-2020.)
© 2000 American Association for Clinical Chemistry, Inc.

Letters

Long-Term Stability of Nelfinavir Mesylate in Human Plasma

Michele L. Turner and Edward P. Acostaa

University of Alabama at Birmingham, Department of Clinical Pharmacology, Birmingham, AL 35294-0019
a Address correspondence to this author at: University of Alabama at Birmingham, Department of Clinical Pharmacology, 1530 3rd Ave. South, VH 116, Birmingham, AL 35294-0019. Fax 205-975-4871; e-mail Edward.Acosta@ccc.uab.edu.


To the Editor:

Nelfinavir mesylate (NFV) is an HIV protease inhibitor approved for the treatment of HIV infection. Since its introduction, NFV has become a common component of standard highly active antiretroviral regimens. Although the drug has been available since 1997, the pharmacokinetic and pharmacodynamic properties of NFV and its active hydroxy-t-butylamide (M8) metabolite have not been well characterized. We recently completed investigations into the stability of NFV and M8 in plasma stored at -20 and -70 °C for up to 19 months. We observed significant degradation of both compounds in heparinized plasma samples stored at -20 °C. These results may have implications for those involved with the collection and analysis of NFV and M8 pharmacokinetic data.

To facilitate our investigations, we prepared NFV and M8 calibrators in drug-free heparinized . . . [Full Text of this Article]


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.